With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better
Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes. The post With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better appeared first on MedCity News.
